There are 2949 resources available
1390P - Impact of adding viagenpumatucel-L to nivolumab in non-small cell lung cancer (NSCLC) patients with low levels of tumour infiltrating lymphocytes
Presenter: Idris Bahce
Session: E-Poster Display
Resources:
Abstract
1391P - Phase III confirmatory efficacy and safety study of proposed bevacizumab biosimilar (MYL-1402O) compared with avastin, in the first-line treatment of patients with stage IV non-squamous non-small cell lung cancer (nsNSCLC)
Presenter: Mark Socinski
Session: E-Poster Display
Resources:
Abstract
1392P - Brigatinib in patients with ALK-positive advanced non-small cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)
Presenter: Renaud Descourt
Session: E-Poster Display
Resources:
Abstract
1393P - Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immune-oncology alone or in combination with chemotherapy
Presenter: Giuseppe Luigi Banna
Session: E-Poster Display
Resources:
Abstract
1394P - Deep learning model to predict clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Arielle Elkrief
Session: E-Poster Display
Resources:
Abstract
1395P - Who will maintain as long-term responders more than 3 years with first- or second-generation EGFR TKI among EGFR mutant NSCLC?
Presenter: Ja Hyun Yeo
Session: E-Poster Display
Resources:
Abstract
1396P - Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM cohort: The ELY study
Presenter: Pascaline Boudou Rouquette
Session: E-Poster Display
Resources:
Abstract
1397P - High incidence of treatment-related adverse events after combination EGFR tyrosine-kinase inhibitor and immune checkpoint inhibitors in EGFR-mutated metastatic non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Wai Ka Daisy Chan
Session: E-Poster Display
Resources:
Abstract
1398P - Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI)
Presenter: Alessandro Dal Maso
Session: E-Poster Display
Resources:
Abstract
1399P - Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
Presenter: Janakiraman Subramanian
Session: E-Poster Display
Resources:
Abstract